Hjem › Brystkreft › Arizona › Tucson
Kliniske studier for Brystkreft i Tucson, AZ
20 studier for Brystkreft søker deltakere på steder i og rundt Tucson (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RekruttererFase 3
- The University of Arizona Cancer Center - North Campus ( Site 0055), Tucson
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RekruttererFase 2
- The University of Arizona Cancer Center - North Campus, Tucson
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- University of Arizona Cancer Center ( Site 0035), Tucson
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutterer
- University of Arizona Cancer Center, Tucson
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruttererFase 3
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekruttererFase 3
- Arizona Clinical Research Center, Inc., Tucson
- University of Arizona Cancer Center, Tucson
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
RekruttererFase 1/2
- University of Arizona Cancer Center, Tucson
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekruttererFase 1/2
- University of Arizona, Tucson
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RekruttererFase 3
- University of Arizona-Cancer Center, Tucson
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekruttererFase 3
- Tucson Medical Center HealthCare, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- USOR Arizona Oncology Associates, Tucson
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RekruttererFase 2
- University of Arizona Cancer Center - Prevention Research Clinic, Tucson
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RekruttererFase 3
- University of Arizona - Cancer Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekruttererFase 1
- The University of Arizona Cancer Center, Tucson
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruttererFase 1
- The University of Arizona Cancer Center, Tucson
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Arizona, Tucson
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RekruttererObservasjonsstudie
- Arizona Oncology Associates, PC - HOPE, Tucson
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekruttererFase 2
- Arizona Oncology Associates, Tucson
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
Rekrutterer
- University of Arizona, Tucson
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RekruttererObservasjonsstudie
- Arizona Oncology, Tucson
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Tucson
- Fedme18 studier
- Ikke-småcellet lungekreft17 studier
- Overvekt15 studier
- Metastatisk kreft14 studier
- Kreft (alle typer)12 studier
- Kardiovaskulær sykdom12 studier
- Kolorektal kreft11 studier
- Prostatakreft11 studier
- Type 2-diabetes11 studier
- Steatotisk leversykdom10 studier
- Hjertesvikt10 studier
- Høyt blodtrykk10 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.